Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-26T15:55:30.508Z Has data issue: false hasContentIssue false
  • English
  • Français

Implications of pharmaceutical cost controls for medical research

Published online by Cambridge University Press:  13 June 2014

Declan P. Doogan
Declan P. Doogan*
Affiliation:
Pfizer Limited, Sandwich, Kent, CT13 9NJ, England
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Irish Journal of Psychological Medicine , Volume 10 , Issue 3 , October 1993 , pp. 136 - 138
Copyright
Copyright © Cambridge University Press 1968

References

1.The health of the nation: a strategy for health in England. London: HMSO, 1986.Google Scholar
2. PMA, In development AIDS Medicines, Drugs and Vaccines Survey Report 1991.Google Scholar
3. Research for health: a progress report on the NHS R&D strategy. Journal of the Foundation for Science & Technology 1992; Autumn.Google Scholar
4.Song, F, Freemantle, N, TA, Sheldon, et al.Selective serotonive reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993; 306: 683–7.CrossRefGoogle ScholarPubMed